joe iniowa

$GANX Gain Therapeutics on NPR this week and presenting Phase 1b Parkinsons data at GBA1 Conference on Friday. BioTech Nation ... with Dr. Moira Gunn | A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics biotechnation.com/episodes/a-dif…

$GANX New NPR interview out in front of this week's GBA1 data presentation. BioTech Nation ... with Dr. Moira Gunn | A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics biotechnation.com/episodes/a-dif…

$GANX New NPR interview out. BioTech Nation ... with Dr. Moira Gunn | A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics biotechnation.com/episodes/a-dif…

The Most Disconnected $1 Stock I’ve Ever Seen (Massive) 👉(youtu.be/eOaInFFqPjE)👈

$GANX Gain Therapeutics will present at GBA1 conference extended data of current Phase 1b Parkinsons trial where they have reversed Parkinson's in 80% of patients at 150 days. Next up 180+ day data.

What if Parkinson’s didn’t have to get worse? $GANX reported updated data showing no decline in motor scores – something rarely seen in this disease. I sat down with CEO Gene Mack again to break it all down 👇 youtu.be/rYCfjSGm3RA

$GANX Gain Therapeutics. Recent scientific article validates Gain's approach that increasing GCase can slow, stop and maybe reverse trajectory of Parkinson’s. assets-eu.researchsquare.com/files/rs-92643…

$COYA $GANX Thats All I Will Say Folks Some Get it, Others Don’t Fundamentals > Stock Price

🚨 Saturday Sassy Small Cap Freedom Fuel: Gain Therapeutics $GANX is turning heads with key conference presentations on next-gen therapies — right as macro tailwinds hit pharma hard! This week’s updates drove solid momentum and attention. @GainThera is building the future of precision medicine the pro-America way! Full Details: markets.businessinsider.com/news/stocks/ga… #Biotech #Pharma #SmallCap #MAGA #BoldStocks #StockQueen

@Rick_in_Miami My thoughts if they have improved 6 points after about a year of Parkinson’s time which would normally be a plus 4 that's almost a 3 year improvement. Plus getting smell back is reversing.

@Microcapreturns I would say it *may* be slowing progression! Stopping or reversing progression is not yet show in the 5 months data. Did show to lower bio-markers and keep them lower Still good news for $GANX I may consider adding around $2.00

$GANX Gain Therapeutics Parkinsons showing that it continues to reverse Parkinsons after 150 days. Amazing.

Thank you to loose hands in $GANX for the early birthday present-buying this dip ahead of next weeks conf is more than prudent-nice to be long with an almost legendary group of investors and experts-truly the first disease modifying drug for any central nervous system disease 🥷

🚨 $GANX is a Clinical-Stage Parkinson's Play You Should Know 🔹 Novel Science Developing GT-02287, targeting GBA1-related Parkinson's disease with a first-in-class allosteric approach 🔹 Breakthrough Data Phase 1b showed 81% average reduction in a key Parkinson's biomarker — a first-ever result for a GCase modulator 🔹 Wall Street Watching 5 analysts rate it a Strong Buy with a consensus price target of $7.20 Why $GANX stands out: 🔸 Parkinson's remains one of the largest unmet needs in modern medicine with no approved disease-modifying therapies 🔸 Preclinical data shows GT-02287 reduces mitochondrial stress and enhances neuronal survival 🔸 Presenting at the AD/PD 2026 International Conference in Copenhagen this month ⚠️Clinical-stage biotech with no approved products. Early-stage investing carries significant risk. Do your own due diligence. Communicated Disclaimer - stockresearchtoday.com/ganx/ $TLYS $AGRZ $EONR

$GANX Gap to fill around $3.80. News next week on Parkinson’s drug and data at AD/PD next week. Looking to take out recent high.

$GANX AD/PD conference next week. Expect biomarker data on DDC DOPA-decarboxylase improvement after only 90 days on Gains drug GT-02287. Matches UPDRS 6 point improvement showing reversing Parkinsons.

$GANX Gain Therapeutics presenting data on Parkinsons at AD/PD 3/18. reddit.com/r/GreenWicks/s…

$GANX Gain Therapeutics AD/PD is in 2 weeks. reddit.com/r/pennystocks/…

@MWB741 $GANX Gain Therapeutics Great article. Here is a bunch of recent research. Gain Therapeutics(GANX):  KOL Reports : GT-02287 Shows Signs of Disease Modification gaintherapeutics.wordpress.com/2026/01/14/gai…

$GANX Gain Therapeutics. Looking for new highs before AD/PD in March.

$GANX Gain Therapeutics will be publishing DDC biomarker data at AD/PD in 2 weeks. reddit.com/r/pennystocks/…